Skip to main content

Advertisement

SpringerLink
Log in

An update into the pathophysiological role of HER2 in cancer: therapeutic implications

  • Editorial
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Olayioye MA, Neve RM, Lane HA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167

    Article  PubMed  CAS  Google Scholar 

  2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137

    Article  PubMed  CAS  Google Scholar 

  3. Massagué J, Pandiella A (1993) Membrane-anchored growth factors. Annu Rev Biochem 62:515–541

    Article  PubMed  Google Scholar 

  4. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  PubMed  CAS  Google Scholar 

  5. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225

    Article  PubMed  CAS  Google Scholar 

  6. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  7. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  PubMed  CAS  Google Scholar 

  8. Cruz JJ, Ocana A, Del Barco E et al (2007) Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 18:421–430

    Article  PubMed  CAS  Google Scholar 

  9. Molina MA, Saez R, Ramsey EE et al (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:347–353

    PubMed  CAS  Google Scholar 

  10. Scaltriti M, Rojo F, Ocana A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628–638

    Article  PubMed  CAS  Google Scholar 

  11. Ocana A, Cruz JJ, Pandiella A (2006) Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 29:90–95

    Article  PubMed  CAS  Google Scholar 

  12. Hudis CA (2007) Trastuzumab — mechanism of action and use in clinical practice. N Engl J Med 357:39–51

    Article  PubMed  CAS  Google Scholar 

  13. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145

    Article  PubMed  CAS  Google Scholar 

  14. Atlas E, Cardillo M, Mehmi I et al (2003) Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 1:165–175

    PubMed  CAS  Google Scholar 

  15. Yuste L, Montero JC, Esparis-Ogando A et al (2005) Activation of ErB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 65:6801–6810

    Article  PubMed  CAS  Google Scholar 

  16. Krane IM, Leder P (1996) NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12:1781–1788

    PubMed  CAS  Google Scholar 

  17. de Alava E, Ocana A, Abad M et al (2007) Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 25:2656–2663

    Article  PubMed  Google Scholar 

  18. Menéndez JA, Mehmi I, Lupu R (2006) Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24:3735–3746

    Article  PubMed  Google Scholar 

  19. Paik S, Kim C, Jeong J et al (2007) Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement):511

    Google Scholar 

  20. Arteaga CL (2006) Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol 24:3722–3725

    Article  PubMed  CAS  Google Scholar 

  21. Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237

    Article  PubMed  CAS  Google Scholar 

  22. Zhou BB, Peyton M, He B et al (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39–50

    Article  PubMed  CAS  Google Scholar 

  23. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127

    Article  PubMed  CAS  Google Scholar 

  24. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852–1857

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Investigación en Oncología Servicio de Oncología Médica, Complejo Hospitalario Universitario de Albacete Univ. Castilla La Mancha, C/ Hermanos Falcó, 37, 02006, Albacete, Spain

    A. Ocaña & A. Pandiella

Authors
  1. A. Ocaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Pandiella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Pandiella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocaña, A., Pandiella, A. An update into the pathophysiological role of HER2 in cancer: therapeutic implications. Clin Transl Oncol 9, 543–544 (2007). https://doi.org/10.1007/s12094-007-0100-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0100-x

Search

Navigation